Why is Bafna Pharma. falling/rising?

As of 25-Aug, Bafna Pharmaceuticals Ltd is experiencing a slight decline in its stock price, currently at 94.90, reflecting a decrease of 0.1 or 0.11%. The stock has been underperforming recently, with a consecutive fall over the last five days, resulting in a significant drop of 18.53% in that period. Despite this downturn, the company has shown strong financial performance in the past year, generating a return of 14.34% while profits have surged by 944%. The stock's ability to service debt is supported by a low Debt to EBITDA ratio of 1.30 times, and it is trading at a discount compared to its peers, indicating a fair valuation. Additionally, institutional investors have increased their stake, suggesting confidence in the company's fundamentals.
In the broader market context, Bafna Pharmaceuticals' recent performance contrasts sharply with the benchmark, as the Sensex has only gained 0.45% over the past week. While the stock has outperformed the market on a year-to-date basis with a return of 24.05% compared to the Sensex's 4.48%, the recent decline highlights a short-term volatility that may be influenced by broader market conditions or sector-specific challenges. The stock's liquidity remains adequate, and rising investor participation could indicate potential for recovery, but the current trend reflects a cautious sentiment among investors.